The study is designed as an intra-patient dose escalation employing a total dose range (over 2 doses, Dose 1 and Dose 2) of between (minimum) 5 x 106 CD19CAR T-cells (plus 20% for thawing losses) and (maximum) 1.1 x 109 CD19CAR T-cells (plus 20% for thawing losses).